Relugolix in Clinical Practice: The Best Route for All?

ABSTRACT: Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.

SUBMITTER: Cordes LM 

PROVIDER: S-EPMC10400131 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature